Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期:
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途:
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma PMID: 29871612
High IDH1 expression is associated with Malignant Transformation of Benign Prostatic Epithelium. PMID: 29331887
Low IDH1 expression level might be an adverse prognostic biomarker for clinical outcomes of ccRCC patients, and two nomograms with IDH1 are potential effective prognostic models for ccRCC. PMID: 30153799
In this review, we summarize current knowledge regarding the function of normal and mutated IDH(socitrate dehydrogenases 1 and 2 ), explain the possible mechanisms through which these mutations might drive malignant transformation of progenitor cells in the central nervous system, and provide a comprehensive review of potential treatment strategies for IDH-mutated malignancies, focusing on gliomas. PMID: 30194083
In patients with supratentorial diffuse gliomas, IDH1-R132H mutations are associated with a more severe phenotype of postoperative epilepsy. These findings support further research into IDH mutations, and the potential for an antiepileptic therapeutic effect of their inhibitors, in patients with glioma-associated epilepsy. PMID: 29172136
Ollier disease is thought to be caused by a post-zygotic mutation of IDH resulting in a mosaicism and IDH mutation is a common genetic event in tumorigenesis. PMID: 30159860
Identification of driver and subclonal mutations in ASXL1 and IDH1/IDH2 genes in an Argentine series of patients with myelofibrosis. PMID: 29761621
an overview of the biological and clinical implications of IDH1 and IDH2 mutations in acute myeloid leukemia (review). PMID: 29543066
genetic association studies in population in Czech Republic: Data suggest that mutations in IDH1 and IDH2 are associated with AML (acute myeloid leukemia); IDH1/2-based monitoring of MRD (minimal residual disease) appears to have prognostic value for residual disease in AML patients. PMID: 30176240
There was significant prognostic difference among the 4 glioma subtypes. Combined IDH and TERT gene mutation analysis may be useful for prognostic subgrouping. Notably, IDH1 wild-type cases can be further subdivided into TERT(+ ) or (-) subgroups with significant prognostic difference. PMID: 30220117
Generation of 2-hydroxyglutarate by mutated IDH1/2 leads to the activation of mTOR by inhibiting KDM4A. PMID: 27624942
IDH1 mutation is associated with glioma progression. PMID: 29016871
promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate dehydrogenase (IDH) mutation, is reported. PMID: 29396294
IDH1 and B7H3 cannot be used as independent prognostic factors, co-expression of IDH1 and B7H3 significantly correlated with the prognosis of CRC patients and may serve as a combined predictive marker. Thus, the correlation between IDH1 and B7H3 has been proven in vivo and in vitro. PMID: 29871819
Co-administration of VOR did not increase the overall response rate (P = 0.84) or overall survival (OS; P = 0.32). Specifically, no benefit was identified in either de novo or relapsed AML. Mutations in the genes CDKN2A (P = 0.0001), IDH1 (P = 0.004), and TP53 (P = 0.003) were associated with reduced OS PMID: 28765326
IDH mutant gliomas are less aggressive, occur in younger patients, are easier to resect, more chemosensitive, and associated with longer survival when compared with IDH wild-type tumors, regardless of histologic grade. PMID: 29369751
IDH1 gene mutation is exclusive in supratentorial Brain Tumors and more frequent in secondary ones, with a greater survival trend and better progression free survival in patients who carry it. PMID: 28948065
we elucidated the antitumor effect of curcumol on MGC-803 cells and the involved mechanisms related to the induction of apoptosis, the increase of ROS, the decrease of MMP and the downregulation of IDH1. PMID: 29039582
Study provides the first evidence that ID1 conferred oxaliplatin resistance in hepatocellular carcinoma proliferation by activating the pentose phosphate pathway. PMID: 29169374
No correlation between IDH1/2 mutation status and sensitivity for NAMPT inhibitors was observed. Strikingly, higher methylation of the NAPRT promoter was observed in high-grade versus low-grade chondrosarcomas. In conclusion, this study identified NAMPT as a potential target for treatment of chondrosarcoma PMID: 28860121
IDH1 mutation, karyotype risk and the revised International Prognostic Scoring System risk category were independent inferior prognostic factors. PMID: 28873367
Results highlight that non-canonical IDH mutations are relatively common in grade II and III gliomas: it is therefore important to analyze exon 4 of both IDH1 and IDH2 in these tumors. They also demonstrate that all IDH mutations, including the non-canonical ones are clonally distributed, a finding consistent with their driver role in gliomagenesis. PMID: 28748342
IDH1 mutation promotes gliomagenesis not by altering cell growth but by arresting differentiation of Neural Stem Cells, which become locked in a self-renewing and brain-invasive state. PMID: 29091765
Data demonstrate that IDH1 mutation reduces the malignant progression of glioma by causing a less aggressive phenotype of GSCs which are involved in the Wnt/betacatenin signaling. PMID: 29115585
Results demonstrated that wild-type IDH1 is over-expressed in lung adenocarcinoma which probably promoted tumor progression via increasing cancer stem cells survival. PMID: 29537891
Low expression of IDH1 is associated with osteosarcoma. PMID: 28534992
Patients with grade II gliomas showed a higher rate of IDH1 and IDH2 mutations and seizures than patients with grade III and IV gliomas--{REVIEW} PMID: 29288860
current meta-analysis identified that IDH1 mutation was correlated to a higher preoperative seizure incidence in low-grade gliomas PMID: 29414139
inhibition of Bcl-xL induces significantly more apoptosis in IDH1-mutated cells than in wild-type IDH1 cells. PMID: 29057925
The rare occurrence of IDH1 mutant high-grade thalamic gliomas strongly suggested that the high-grade thalamic glioma is another distinct tumor entity as compared to the high-grade superficial gliomas. PMID: 28869450
Our findings indicate that IDH1WT glioma have a typical Warburg phenotype whereas in IDH1MUT glioma the TCA cycle, rather than glycolytic lactate production, is the predominant metabolic pathway. Our data further suggest that the TCA in IDH1MUT glioma is driven by lactate and glutamate anaplerosis to facilitate production of alpha-KG, and ultimately D-2-HG. PMID: 28467784
The aim of this study is to determine the prevalence of IDH mutations and EGFR amplifications in the population of the northeast region of Morocco and then to compare the results with other studies. PMID: 28785587
this epigenetic antagonism precedes malignant transformation and can be observed in preleukemic LSK cells from Idh2(R140Q) or Dnmt3a(R882H) single-mutant and Idh2(R140Q)/Dnmt3a(R882H) double-mutant mice. IDH/DNMT3A double-mutant acute myeloid leukemia (AML)manifested upregulation of a RAS signaling signature and displayed unique sensitivity to MEK inhibition ex vivo as compared with AMLs with either single mutation. PMID: 28408400
IDH1(R314C) lacks isocitrate-to-alpha-ketoglutarate conversion activity due to reduced affinity for NADP(+), and differs from the IDH1(R132) mutants in that it does not produce D-2-hydroxyglutarate. PMID: 27460417
Findings demonstrated that miR-148a promotes glioma cell invasion and tumorigenesis by downregulating GADD45A. Findings provide novel insights into how GADD45A is downregulated by miR-148a in IDH1R132H glioma PMID: 28445981
Glioblastoma multiforme HIF1-alpha and serum VEGF levels were found to be significantly increased in IDH1-mutated tumor tissues.Mutated IDH1 may contribute to carcinogenesis via induction of HIF-1 alpha pathway in primary glioblastoma multiforme. PMID: 28667042
IDH1 mutation is associated with 1p19q co-deletion diffuse glioma. PMID: 28340142
DNA mutational analysis in IDH1 in acute myeloid leukemia. PMID: 27071442
Authors conclude that PROX1 is a new prognostic biomarker for 1p19q non-codeleted high-grade astrocytomas that have progressed from pre-existing low-grade tumors and harbor IDH1 mutations. PMID: 27626492
In primary human acute myeloid leukemia samples, the 2-hydroxyglutarate levels observed in samples with mutant IDH1 or IDH2 status were higher than those observed in samples without an enzyme mutation, similar to what was observed in the original study (Figure 5C; Ward et al., 2010). PMID: 28653623
Results present a unique phenotype of isocitrate dehydrogenase-mutation primary de novo glioblastomas arising from insular cortex region, the molecular backgrounds of which are similar to secondary glioblastomas. PMID: 28116838
These findings suggest that IDH1 upregulation represents a common metabolic adaptation by glioblastoma to support macromolecular synthesis, aggressive growth, and therapy resistance. PMID: 28564604
Patients with low IDH1-R132H expression had a poor overall survival. Our data indicate that IDH1-R132H expression could be used as a predictive marker of prognosis for patients with gastrointestinal cancer. PMID: 27655638
ATRX deficiency was mutually exclusive with LOH. Conversely, ATRX-proficient tumours immunoreactive for R132H-mutant isocitrate dehydrogenase 1 (IDH1) showed a high rate (85%) of LOH. PMID: 26016385
FZD7 and IDH1 were assessed by immunohistochemistry in tissue microarrays. PMID: 27409829
TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. PMID: 28218607
our finding that the expression of MCT1 and MCT4 is reduced in mutant IDH1 gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 tumors and has important implications for our understanding of these tumors and their treatment PMID: 27144334
IDH1/2 mutations induce a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase inhibitors PMID: 28148839
To confirm this result, we analyzed survival data from 142 LGGs from TCGA with IDH1/IDH2 mutations and no 1p19q codeletion. Despite the high rate of censured data, we found that CNLOH 17p, including the TP53 locus, was associated with better outcome (OR = 0.27; p = .026) PMID: 27401888
Results suggest that to better treat gliomas, isocitrate dehydrogenase (NADP(+)) 1 (IDH-1) mutation status should be included when determining WHO2007 grade in glioma patients. PMID: 27120786
顯示更多
收起更多
相關(guān)疾病:
Glioma (GLM)
亞細(xì)胞定位:
Cytoplasm, cytosol. Peroxisome.
蛋白家族:
Isocitrate and isopropylmalate dehydrogenases family